Comparison of Anti-Microbial Susceptibility of Pseudomonas Aeruginosa Causing Community and Hospital Acquired Urinary Tract Infection at a Tertiary Care Hospital
Abstract
Introduction: Urinary Tract Infections (UTIs) are a leading cause of morbidity in both community and healthcare settings, with Healthcare-Associated UTIs (HAUTIs) being the most prevalent healthcare-acquired infections. The emergence of multidrug-resistant pathogens, such as Pseudomonas aeruginosa, poses significant challenges to effective treatment.
Objectives: This study investigates the prevalence of Pseudomonas aeruginosa in Community- Acquired (CA-UTI) and Hospital-Acquired (HA-UTI) urinary tract infections and evaluates their antimicrobial susceptibility profiles to guide therapeutic strategies.
Materials and Methods: Urine samples were collected from outpatients (classified as CA-UTI) and discharged patients with urinary catheters within five days post-discharge (classified as HA-UTI). Uropathogens were isolated and Antimicrobial Susceptibility Testing (AST) was performed to assess resistance patterns.
Statistical Analysis: Data were analyzed using descriptive statistics, including mean, median, frequency and standard deviation with statistical significance set at p<0.05.
Results: Between April 2023 and March 2024, total of 4,590 urine cultures were analyzed, identifying Pseudomonas aeruginosa in 219 cases (163 CA-UTI, 56 HA-UTI). Susceptibility rates for CA-UTI isolates were: Cefepime (42.9%), Ciprofloxacin (31.9%), Imipenem (61.1%), Meropenem (65.6%), Netilmicin (45.3%), Norfloxacin (19.6%), Piperacillin (49.0%), Piperacillin-Tazobactam (65.0%), Ticarcillin (36.1%),…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.